Sunday, October 22, 2017

Kalbitor Approved for Treatment of Hereditary Angiodema (HAE)

FDA Approves Kalbitor for Treating Potentially Life-Threatening Attacks of Hereditary Angioedema The U.S. Food and Drug Administration approved Kalbitor (ecallantide) on Dec. 1 to treat sudden and potentially life-threatening fluid buildup that can occur in people with a rare genetic condition known as hereditary angioedema (HAE). HAE is caused by a defect in the blood […]

READ COMPLETE ARTICLE »